(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer with "a very poor prognosis".
(Alliance News) - Stock prices in London were mixed at midday on Thursday, as the FTSE 100 outperformed the mid-cap index as investors focused on the upcoming US jobs report for further clues on the F...
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.
(Alliance News) - Hutchmed China Ltd on Thursday reported positive phase two data for fanregratinib in patients with intrahepatic cholangiocarcinoma, showing clinically meaningful and durable response...
(Alliance News) - Hutchmed China Ltd on Friday said phase III trial results for its investigational drug sovleplenib showed significant efficacy and a favourable safety profile in patients with warm a...